Atamyo Therapeutics

Description

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD2I/R9 and LGMD2C/R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

Company members

Stephane Degove, co-founder and CEO. Pr. Isabelle Richard, co-founder and CSO. Dr Sophie Olivier, CMO. Catherine Cancian, CTO

HealthTech Innovation Days - 6th edition is an event organized by HealthTech For Care.

HealthTech For Care is an endowment fund (non-for profit organization) whose primary mission is to advocate for universal access to healthcare for all European patients, with a specific focus on advanced medical technologies and innovative drugs. The fund's initiatives and events with a European dimension gather all stakeholders involved in the health innovation value chain, fostering better coordination within the European health ecosystem. HealthTech For Care is administered by a board of European experts.

For any request: contact@htfc-eu.com
Where to find us? Healthtech For Care, 10 Place de Catalogne, 75014 Paris

Atamyo Therapeutics

Description

Company members

© HealthTech For Care 2022-2024 - All rights reserved

Cookies Policy

Legal notice

Privacy Policy